-
公开(公告)号:US20190169166A1
公开(公告)日:2019-06-06
申请号:US16323863
申请日:2017-08-09
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Jun FUJIMOTO , Xin LIU , Osamu KURASAWA , Terufumi TAKAGI , Douglas Robert CARY , Hiroshi BANNO , Yasutomi ASANO , Takuto KOJIMA
IPC: C07D401/12 , C07D239/42 , A61P35/00
Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US20210363130A1
公开(公告)日:2021-11-25
申请号:US17042394
申请日:2019-03-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Koji ONO , Masahiro ITO , Toshio TANAKA , Moriteru ASANO , Takaharu HIRAYAMA , Jun FUJIMOTO , Nobuki SAKAUCHI , Yasuhiro HIRATA , Akinori TOITA , Nao MORISHITA , Hironori KOKUBO , Yasuhiro IMAEDA , Hironobu MAEZAKI , Douglas Robert CARY , Ryo MIZOJIRI , Nobuo CHO , Hiroshi BANNO , Hidekazu TOKUHARA , Yasuyoshi ARIKAWA
IPC: C07D401/14 , A61P35/00 , C07D401/12 , C07D405/14 , C07D405/12 , C07D213/84 , C07D403/14 , C07D403/12 , C07D471/10 , C07D487/10 , C07D495/10
Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US20170044132A1
公开(公告)日:2017-02-16
申请号:US15304623
申请日:2015-04-16
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Takaharu HIRAYAMA , Jun FUJIMOTO , Douglas Robert CARY , Masanori OKANIWA , Yasuhiro HIRATA
IPC: C07D401/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D401/14 , C07D487/08 , C07D491/08 , C07D405/14 , C07D487/04 , C07D491/107 , C07D417/04 , C07D409/14 , C07D498/08
CPC classification number: C07D401/04 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/553 , C07D213/64 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/08 , C07D491/107 , C07D498/08
Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
Abstract translation: (在该式中,符号如说明书中所定义)或其盐。
-
公开(公告)号:US20230117295A1
公开(公告)日:2023-04-20
申请号:US18075853
申请日:2022-12-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Koji ONO , Masahiro ITO , Toshio TANAKA , Moriteru ASANO , Takaharu HIRAYAMA , Jun FUJIMOTO , Nobuki SAKAUCHI , Yasuhiro HIRATA , Akinori TOITA , Nao MORISHITA , Hironori KOKUBO , Yasuhiro IMAEDA , Hironobu MAEZAKI , Douglas Robert CARY , Ryo MIZOJIRI , Nobuo CHO , Hiroshi BANNO , Hidekazu TOKUHARA , Yasuyoshi ARIKAWA
IPC: C07D401/14 , C07D403/14 , C07D401/12 , C07D471/10 , C07D495/10 , C07D405/12 , C07D403/12 , C07D213/84 , C07D487/10 , C07D405/14 , A61P35/00
Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号:US20150299188A1
公开(公告)日:2015-10-22
申请号:US14423310
申请日:2013-08-23
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masaki OGINO , Zenichi IKEDA , Jun FUJIMOTO , Yusuke OHBA , Naoki ISHII , Takuya FUJIMOTO , Tsuneo ODA , Naohiro TAYA , Toshiro YAMASHITA , Nobuyuki MATSUNAGA
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K9/2018 , A61K9/4858 , C07D239/80 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/12 , C07D413/04 , C07D417/12 , C07D487/04 , C07D513/04 , C07D519/00
Abstract: Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.
Abstract translation: 提供具有优异的FLAP抑制作用并可用作动脉硬化等的预防或治疗剂及其盐的化合物。 本发明涉及由下式表示的化合物,其中各符号如本说明书所定义,或其盐。
-
-
-
-